CNTO-5825

CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13) . CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis[1].

Product Specifications

UNSPSC

12352203

Target

Interleukin Related

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

[CNTO-5825]

References & Citations

[1]van Hartingsveldt B, et al. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75 (5) :1289-98.